Vista Capital Partners Inc. acquired a new position in shares of Colgate-Palmolive Company (NYSE:CL – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 5,831 shares of the company’s stock, valued at approximately $498,000.
A number of other institutional investors and hedge funds have also modified their holdings of the company. Hamel Associates Inc. boosted its stake in Colgate-Palmolive by 524.3% during the third quarter. Hamel Associates Inc. now owns 29,281 shares of the company’s stock worth $2,498,000 after buying an additional 24,591 shares in the last quarter. Moors & Cabot Inc. increased its holdings in Colgate-Palmolive by 1.0% in the 3rd quarter. Moors & Cabot Inc. now owns 42,266 shares of the company’s stock valued at $3,606,000 after buying an additional 409 shares during the period. Money Concepts Capital Corp raised its stake in shares of Colgate-Palmolive by 2.6% in the 3rd quarter. Money Concepts Capital Corp now owns 47,726 shares of the company’s stock valued at $4,072,000 after buying an additional 1,220 shares in the last quarter. Allworth Financial LP raised its stake in shares of Colgate-Palmolive by 17.9% in the 3rd quarter. Allworth Financial LP now owns 38,674 shares of the company’s stock valued at $3,546,000 after buying an additional 5,870 shares in the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of Colgate-Palmolive by 64.0% in the 3rd quarter. Fisher Asset Management LLC now owns 100,653 shares of the company’s stock valued at $8,588,000 after buying an additional 39,268 shares in the last quarter. 80.41% of the stock is currently owned by institutional investors.
Trending Headlines about Colgate-Palmolive
Investors following CL have been watching these headlines:
- Neutral Sentiment: The analyst revisions were not uniformly positive: Zacks also lowered several quarterly estimates, including Q1 and Q2 FY2027 and Q1 and Q2 FY2028, while increasing others. The overall picture is therefore mixed rather than a broad-based upgrade. Zacks Research forecast coverage
- Neutral Sentiment: A comparison with Kimberly-Clark highlighted Colgate-Palmolive’s leading global oral-care position and its pet-nutrition business as potential growth diversifiers, but the article did not report a new company-specific catalyst. Colgate-Palmolive vs. Kimberly-Clark
- Negative Sentiment: A Colgate-Palmolive executive vice president sold $401,677 worth of company shares. Insider sales can weigh on sentiment, although a single transaction does not necessarily indicate a change in the company’s outlook. Insider Selling: Colgate-Palmolive EVP Sells Stock
Insider Activity
In related news, insider John Hazlin sold 23,376 shares of Colgate-Palmolive stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $99.15, for a total transaction of $2,317,730.40. Following the completion of the transaction, the insider directly owned 27,021 shares of the company’s stock, valued at $2,679,132.15. This trade represents a 46.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Panagiotis Tsourapas sold 19,938 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $98.74, for a total transaction of $1,968,678.12. Following the completion of the transaction, the chief operating officer owned 9,111 shares in the company, valued at approximately $899,620.14. This trade represents a 68.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 77,414 shares of company stock valued at $7,613,786. Company insiders own 0.43% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on CL shares. Raymond James Financial raised their price objective on shares of Colgate-Palmolive from $100.00 to $102.00 and gave the stock an “outperform” rating in a report on Monday, August 3rd. Jefferies Financial Group reissued a “hold” rating and issued a $89.00 target price (up from $88.00) on shares of Colgate-Palmolive in a research note on Monday, August 3rd. Weiss Ratings lowered shares of Colgate-Palmolive from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 2nd. JPMorgan Chase & Co. dropped their price target on shares of Colgate-Palmolive from $104.00 to $102.00 and set an “overweight” rating for the company in a research report on Monday, November 2nd. Finally, Morgan Stanley raised their price target on shares of Colgate-Palmolive from $104.00 to $111.00 and gave the stock an “overweight” rating in a research note on Monday, November 2nd. Thirteen analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $101.22.
Get Our Latest Stock Analysis on Colgate-Palmolive
Colgate-Palmolive Stock Performance
Colgate-Palmolive stock opened at $99.62 on Monday. The company has a debt-to-equity ratio of 11.23, a current ratio of 0.96 and a quick ratio of 0.63. The stock has a fifty day moving average price of $90.94 and a two-hundred day moving average price of $90.29. Colgate-Palmolive Company has a 52-week low of $75.96 and a 52-week high of $101.18. The firm has a market capitalization of $79.19 billion, a P/E ratio of 39.07, a P/E/G ratio of 4.51 and a beta of 0.31.
Colgate-Palmolive (NYSE:CL – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Colgate-Palmolive had a return on equity of 607.88% and a net margin of 9.65%. The company had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.34 billion. During the same period last year, the business earned $0.91 earnings per share. The business’s revenue was up 4.6% on a year-over-year basis. As a group, analysts anticipate that Colgate-Palmolive Company will post 3.92 EPS for the current fiscal year.
Colgate-Palmolive Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Friday, November 13th. Investors of record on Tuesday, October 20th were given a dividend of $0.53 per share. The ex-dividend date was Tuesday, October 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.1%. Colgate-Palmolive’s dividend payout ratio (DPR) is 83.14%.
About Colgate-Palmolive
Colgate-Palmolive is a global consumer products company whose business spans oral care, personal care, home care and pet nutrition. Its products include toothpaste, toothbrushes, mouthwashes, soaps, shampoos, cleaning products and pet food. The company’s best-known brands include Colgate, Palmolive, elmex, Softsoap, Ajax and Hill’s Pet Nutrition. It sells products through retail and other channels in markets around the world. Founded in 1806 by William Colgate as a soap and candle business in New York City, the company has grown into an international manufacturer of household and personal care products.
Read More
- Five stocks we like better than Colgate-Palmolive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.
